Objective This clinical trial was conducted to investigate efficacy and safety of sofebuvir and redipavir combination in the treatment of patients with chronic hepatitis C(CHC).Methods Forty-eight patients with CHC were enrolled in our hospital between February 2017 and March 2023,and were randomly divided into observation(n=24)and control group(n=24),receiving sofebuvir and redipavir combination for 12 weeks or peginterferon-α and ribavirin combination for 24 weeks,respectively.Rapid virological response(RVR),end of treatment(EOT)virological response(ETVR)and sustained virological response(SVR)were recorded.Results The clinical materials including HCV genotypes at baseline in the two groups were comparable(P＞0.05);RVR,ETVR and SVR in the DAA-treated patients were 75.0％,95.8％and 95.8％,all much higher than 58.3％,70.8％and 66.7％(P＜0.05)in peginterferon-α-treated patients;by end of antiviral treatment,platelet and white blood cell counts in DAA-treated patients were(201.5±22.3)×10 9/L and(6.5±1.4)×10 9/L,both significantly higher than[(137.6±15.0)×10 9/L and(3.7±1.3)×10 9/L,P＜0.05],while serum ALT level was(36.2±4.3)U/L,much lower than[(60.8±5.4)U/L,P＜0.05]in peginterferon-α-treated patients;during antiviral treatment,adverse events rates,such as fever occurred in 83.3％,granulocytopenia in 62.5％and thrombocytopenia in 41.7％in peginterferon-α-treated patients.Conclusion Sofebuvir and redipavir combination therapy in treatment of patients with CHC has a satisfactory efficacy and relatively less adverse events,which warrants widespread clinical application.
维普
万方数据